LifeStance Health Group (LFST) to Release Quarterly Earnings on Thursday

Key Points

• LifeStance Health Group (LFST) is set to announce its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.03) per share and revenue of $345.05 million.
• The stock opened at $4.23 and has a market capitalization of $1.64 billion, with a 52-week range between $4.08 and $8.61.
• Wall Street analysts generally have a positive outlook, with an average rating of "Moderate Buy" and a consensus target price of $8.42.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect LifeStance Health Group to post earnings of ($0.03) per share and revenue of $345.05 million for the quarter.

LifeStance Health Group Stock Up 2.0%

Shares of LifeStance Health Group stock traded up $0.08 during trading on Monday, hitting $3.87. 839,392 shares of the stock traded hands, compared to its average volume of 1,846,772. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19. The stock's fifty day simple moving average is $4.96 and its 200 day simple moving average is $6.31. The firm has a market cap of $1.50 billion, a P/E ratio of -38.65 and a beta of 1.13. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.61.

Insider Transactions at LifeStance Health Group

In related news, insider Ujjwal Ramtekkar sold 16,000 shares of the company's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $5.94, for a total value of $95,040.00. Following the transaction, the insider directly owned 113,435 shares of the company's stock, valued at $673,803.90. This represents a 12.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in LifeStance Health Group by 1.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company's stock valued at $4,100,000 after buying an additional 11,331 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of LifeStance Health Group by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company's stock worth $952,000 after acquiring an additional 4,169 shares during the period. Royal Bank of Canada raised its holdings in shares of LifeStance Health Group by 63.4% during the first quarter. Royal Bank of Canada now owns 70,248 shares of the company's stock worth $468,000 after purchasing an additional 27,244 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company's stock valued at $343,000 after purchasing an additional 35,554 shares during the period. 85.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LFST has been the subject of several research reports. KeyCorp began coverage on shares of LifeStance Health Group in a research report on Tuesday, April 8th. They issued an "overweight" rating and a $9.00 price target for the company. BTIG Research started coverage on shares of LifeStance Health Group in a research note on Friday, July 25th. They issued a "buy" rating and a $8.00 price objective for the company. Finally, UBS Group raised LifeStance Health Group from a "neutral" rating to a "buy" rating and set a $8.50 target price on the stock in a research report on Tuesday, May 27th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.42.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.